Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
Rajni Sethi, Nicholas SanfilippoDepartment of Radiation Oncology, New York University Langone Medical Center, New York, NY, USAAbstract: Hormonal deprivation therapy is well established for the treatment of locally advanced and metastatic prostate cancer, as well as the adjuvant treatment of some pa...
Enregistré dans:
Auteurs principaux: | Rajni Sethi, Nicholas Sanfilippo |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2009
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/72f39d373bb845b7bb19979e8e7aae54 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
par: Tunn UW, et autres
Publié: (2013) -
Comparison between selected hormone and protein levels in serum and prostate tissue homogenates in men with benign prostatic hyperplasia and metabolic disorders
par: Grzesiak K, et autres
Publié: (2018) -
Degarelix and its therapeutic potential in the treatment of prostate cancer
par: Christian Doehn, et autres
Publié: (2009) -
Is there an optimal management for localized prostate cancer?
par: Jaspreet Singh, et autres
Publié: (2010) -
Serum total prostate-specific antigen values in men with symptomatic prostate enlargement in Nigeria: role in clinical decision-making
par: Nnabugwu II, et autres
Publié: (2014)